Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline Review, H2 2016’, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)

The report reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) therapeutics and enlists all their major and minor projects

The report assesses Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bexion Pharmaceuticals LLC

EpiZyme Inc

Merck & Co Inc

Novartis AG

Pfizer Inc

Plexxikon Inc

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) Overview 6

Therapeutics Development 7

Pipeline Products for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview 7

Pipeline Products for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Comparative Analysis 8

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics under Development by Companies 9

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics under Investigation by Universities/Institutes 10

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Products under Development by Companies 13

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Products under Investigation by Universities/Institutes 14

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development 15

Bexion Pharmaceuticals LLC 15

EpiZyme Inc 16

Merck & Co Inc 17

Novartis AG 18

Pfizer Inc 19

Plexxikon Inc 20

Vyriad Inc 21

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

axitinib - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

BXQ-350 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

everolimus - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

ganetespib - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Oncolytic Virus to Target CD46 for Oncology - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

pembrolizumab - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

pexidartinib - Drug Profile 97

Product Description 97

Mechanism Of Action 97

R&D Progress 97

Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

tazemetostat - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects 109

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Product Development Milestones 110

Featured News & Press Releases 110

Dec 26, 2013: UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer 110

Appendix 111

Methodology 111

Coverage 111

Secondary Research 111

Primary Research 111

Expert Panel Validation 111

Contact Us 111

Disclaimer 112

List of Tables

List of Tables

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H2 2016 7

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Bexion Pharmaceuticals LLC, H2 2016 15

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by EpiZyme Inc, H2 2016 16

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Merck & Co Inc, H2 2016 17

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Novartis AG, H2 2016 18

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Pfizer Inc, H2 2016 19

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Plexxikon Inc, H2 2016 20

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Pipeline by Vyriad Inc, H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 30

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Dormant Projects, H2 2016 109

List of Figures

List of Figures

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H2 2016 7

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Top 10 Targets, H2 2016 23

Number of Products by Stage and Top 10 Targets, H2 2016 23

Number of Products by Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Molecule Types, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 29

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports